Clinical Trials on Moderate Renal Impairment

Total 13215 results

Novartis Pharmaceuticals

Completed

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Mild and Moderate Renal Impairment

Russian Federation, Germany, Serbia
Novartis Pharmaceuticals

Completed

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Mild Moderate | or Severe Renal Impairment

Germany
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Hypertension With Moderate Renal Impairment

Japan
Merck Sharp & Dohme LLC

Completed

A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)

Moderate Renal Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
UCB Pharma
Parexel

Completed

Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients

Healthy Subjects | Renal Impairments

Japan
Yuhan Corporation

Completed

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Healthy Volunteer | Renal Impairments

Korea, Republic of
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
CSL Behring

Completed

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Acute Myocardial Infarction | Moderate Renal Impairment

United States, Germany, Hungary, Israel, Netherlands
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Liver Diseases | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

Healthy Volunteers | Hepatic Impairment of Moderate Child Pugh Category

France, Hungary
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Daiichi Sankyo, Inc.

Completed

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Moderate Hepatic Impairment

United States
LG Life Sciences

Completed

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (GUARD)

Type 2 DM Patients With Moderate or Severe Renal Impairment

Korea, Republic of
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Moderate Liver Impairment | Severe Liver Impairment

United States
Takeda

Completed

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

Gout | Moderate Renal Impairment

United States
Eisai Inc.

Completed

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Hepatic Impairment; Renal Impairment

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
JW Pharmaceutical

Completed

A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment

Healthy, Renal Impairment

Korea, Republic of
Kowa Research Institute, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

Severe Renal Impairment

United States
Gilead Sciences

Terminated

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Severe Renal Impairment

United States
Centre for Probe Development and Commercialization
St. Joseph's Healthcare Hamilton; McMaster University

Completed

A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function

Renal Function Impairment

Canada
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Affiliated Hospital of Zhengzhou University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Chronic Renal Impairment

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Melbourne Health

Withdrawn

Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Renal Impairment After Cardiac Surgery

Australia
AstraZeneca

Completed

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Renal Impairment | Hepatic Impairment

Bulgaria
Manchester University NHS Foundation Trust
Cardiff University; University of Manchester; National Institute for Health Research... and other collaborators

Completed

The Effectiveness of Portable Electronic Vision Enhancement Systems (p-EVES) for Near Vision in Visual Impairment (p-EVES)

Moderate or Severe Vision Impairment, Both Eyes

United Kingdom
Allecra

Completed

Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects

PK in Patients With Various Degrees of Renal Impairment

Czechia, Hungary
Centre Hospitalier Universitaire de Saint Etienne
GlaxoSmithKline

Completed

Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux. (PROPICE)

Major Orthopaedic Surgery and Renal Impairment

France
Vasopharm GmbH
Winicker Norimed GmbH

Completed

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

Renal Function Impairment in Healthy Volunteers

Germany
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir

Renal Impairment | Hepatic Impairment

China
Takeda

Completed

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Renal Impairment | Hepatic Impairment

Japan
Bracco Diagnostics, Inc

Terminated

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients (RECARE)

Diabetes Mellitus | Chronic Renal Impairment

United States
Duke University
Alzheimer's Association; Duke-NUS Graduate Medical School; Duke Institute for...

Completed

Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease

Mild Cognitive Impairment | Mild to Moderate Cognitive Impairment

United States
VIVUS LLC

Completed

To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

Renal
H. Lundbeck A/S

Terminated

Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

Renal Failure

Germany
AbbVie
Roche-Genentech

Completed

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Renal Impairment | Renal Disease

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Renal Impairment | Kidney Disease | Renal Disease

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Healthy Subjects | Subjects With Renal Impairment

China
Exelixis

Completed

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Healthy | Renal Impairment

United States

3

Subscribe